Stage III Non-Small Cell Lung Cancer
Key Points
Key Points
- Stage III non-small cell lung cancer (NSCLC) represents one of the most heterogenous subgroups of lung cancer. Consequently, it is also the subgroup in which choice and sequence of multimodality treatment varies significantly among clinicians, with variations being observed across and within institutes.
- This guideline reviews the published evidence addressing diagnosis and management of stage III NSCLC and provides evidence-based guidance on the common clinical dilemmas that clinicians may have while evaluating a patient with suspected or known stage III NSCLC.
- Four randomized control trials (RCTs) published in 2022, 2023, and 2024, prompted an amendment to the 2021 guideline.
Diagnosis
...gnosis...
...valuation and S...
...mendation 1.1For patients with suspected stage...
...ion 1.2Following evaluation with CT scan as p...
...ndation 1.3For patients with suspecte...
...dation 1.4For patients who require patholog...
...on 1.5For patients who require pathologic...
...ion 1.6For patients who have suspect...
...e PointBiopsy should generally be performed...
...rgery...
...dation 2.1For patients with stage IIIA (N2) N...
...ommendation 2.2For selected patients...
...ractice Points...
...h stage III NSCLC generally should no...
...sence of oncogenic driver alterations, available...
...s and providers should consider enr...
Treatment
Treatmen...
...uvant Therapy...
...ion 3.1Patients who are planned for...
...ommendation 3.2Patients with stage III NSCL...
...dation 3.3For patients with resectable superior su...
...vant Therapy...
...commendation 4.1Patients with resected...
...commendation 4.2Patients with resect...
...on 4.3For patients with completely resec...
...ectable Disease...
...dation 5.1Patients with stage III NSCLC who...
...ndation 5.2Concurrent chemotherapy...
Recommendation 5.3Patients with stage...
...commendation 5.4Patients with stage III NSCLC...
...ion 5.5Doses higher than 60 Gy and up to 70 Gy...
...on 5.6Patients with stage III NSCLC...
... Recommendation 5.7Patients with stage II...
...ion 5.8(Update): Patients with unresecta...
... Figure 1. Evaluation and Staging in Stage I...
...Management of Stage III NSCLCArrows with...